Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults...

Full description

Saved in:
Bibliographic Details
Main Authors: Karp, Judith E., Vener, Tatiana I., Raponi, Mitch, Ritchie, Ellen K., Smith, B. Douglas, Gore, Steven D., Morris, Lawrence E., Feldman, Eric J., Greer, Jacqueline M., Malek, Sami, Carraway, Hetty E., Ironside, Valerie, Galkin, Steven, Levis, Mark J., McDevitt, Michael A., Roboz, Gail R., Gocke, Christopher D., Derecho, Carlo, Palma, John, Wang, Yixin, Kaufmann, Scott H., Wright, John J., Garret-Mayer, Elizabeth
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2012
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251236/
https://ncbi.nlm.nih.gov/pubmed/22001391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-370825
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items